- Home
- BLND vs BCYC Comparison
BLND vs BCYC Comparison
Compare BLND & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLND | BCYC |
|---|---|---|
| Founded | 2012 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 355.9M | 310.7M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | BLND | BCYC |
|---|---|---|
| Price | $1.65 | $4.10 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 10 |
| Target Price | $4.13 | ★ $13.90 |
| AVG Volume (30 Days) | ★ 3.1M | 501.2K |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.33 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $123,585,000.00 | N/A |
| Revenue This Year | $12.62 | N/A |
| Revenue Next Year | $14.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.18 | $3.95 |
| 52 Week High | $4.49 | $9.18 |
Technical Indicators
Market Signals| Indicator | BLND | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 50.81 | 39.48 |
| Support Level | $1.56 | N/A |
| Resistance Level | $1.67 | $5.31 |
| Average True Range (ATR) | 0.12 | 0.19 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 34.48 | 18.87 |
Price Performance
Historical ComparisonAbout BLND Blend Labs Inc.
Blend Labs Inc is a cloud-based platform software platform that powers the digital interface between financial services firms and consumers. It supports and simplifies applications for mortgages, consumer loans, and deposit accounts. Its operating segment is Blend Platform segment which comprises a suite of products that power the entire origination process from back-end workflows to consumer experience. The key revenue for the company is generated from the Blend Platform segment. Company has it's assets in united states, India and Mexico regions.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.